Odonate Inc

Odonate Inc has a capital structure characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations, and a current ratio of 5.91, suggesting strong short-term liquidity. The company's total equity of $136.1 million is supported by total assets of $167.9 million, with total liabilities of $31.7 million. Despite this, the company reported negative operating and free cash flows of -$113.1 million and -$126.3 million, respectively, in the latest period. Profitability metrics for Odonate Inc are negative, with a return on equity of -92.81% and a return on assets of -75.26%. These figures are significantly below the industry median for pharmaceutical companies, which typically report positive returns on equity and assets. The company's net income of -$126.4 million reflects ongoing losses, consistent with its early-stage development focus. Odonate Inc's revenue is not disclosed in the latest financials, and the company reported $0 in revenue for the most recent period. This suggests that the company is not yet generating commercial revenue and is likely relying on equity financing to fund operations. The absence of revenue concentration data implies that the company is not yet diversified in terms of product or geographic exposure. The company's growth trajectory is not yet defined in terms of revenue, as it has not yet achieved commercial sales. However, the company is investing in its pipeline, as evidenced by a capital expenditure of -$432,000 in the latest period. Analysts have not provided revenue or earnings estimates for the next fiscal year, indicating uncertainty around the company's future performance. Risk factors for Odonate Inc include its reliance on equity financing, as it has no long-term debt and a low dilution risk score. However, the company's liquidity risk is rated as low, and no immediate filing-based liquidity or dilution flags were detected. The company has not issued any recent equity, and there are no indications of near-term dilution pressure. Nevertheless, the absence of revenue and ongoing losses pose significant operational risks. Recent events for Odonate Inc include the continued development of its pipeline, with no significant filings or transcripts indicating major changes in strategy or operations. The company remains in the pre-commercialization phase, and its financial performance is consistent with that of a development-stage biopharmaceutical firm.